Abstract
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have